Literature DB >> 6430802

Antiinflammatory properties of a hydroperoxide compound, structurally related to acetylsalicylic acid.

J J Killackey, B A Killackey, I Cerskus, R B Philp.   

Abstract

3-Hydroperoxy-3-methylphthalide (3-HMP), a structural analog of acetylsalicylic acid (ASA), was found to have some antiinflammatory properties which are distinct from those of ASA. 3-HMP inhibits human platelet aggregation and ATP release in response to low concentrations of collagen but is less effective than ASA. 3-HMP inhibits prostaglandin and thromboxane production from exogenous [14C]arachidonic acid by human platelet lysates in vitro and does so at lower concentrations than ASA (3-HMP IC50 = 10 microM; ASA IC50 = 50 microM). 3-HMP is also more effective than ASA as an inhibitor of prostacyclin-like activity production by rings of rabbit aorta. Human polymorphonuclear (PMN) leukocyte [14C]arachidonic acid metabolism is inhibited by 3-HMP but not ASA. In urethane-anesthetized rats, 3-HMP (10 mg/kg intravenously) is effective in inhibiting PMN leukocyte accumulation in response to intrapleural carrageenan administration whereas ASA is ineffective (100 mg/kg intravenously). This hydroperoxy analog of ASA has antiinflammatory activity which may result from a combination of the ASA-like and hydroperoxide-related pharmacological properties.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430802     DOI: 10.1007/bf00916091

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  37 in total

1.  Resolution of prostaglandin endoperoxide synthase and thromboxane synthase of human platelets.

Authors:  S Hammarström; P Falardeau
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

2.  Aspirin selectively inhibits prostaglandin production in human platelets.

Authors:  J B Smith; A L Willis
Journal:  Nat New Biol       Date:  1971-06-23

3.  Effect of three nonsteroidal anti-inflammatory agents on platelet function and prostaglandin synthesis in vitro.

Authors:  B A McIntyre; R B Philp
Journal:  Thromb Res       Date:  1978-01       Impact factor: 3.944

4.  Unique aspects of the modulation of human neutrophil function by 12-L-hydroperoxy-5,8,10,14-eicosatetraenoic acid.

Authors:  E J Goetzl; H R Hill; R R Gorman
Journal:  Prostaglandins       Date:  1980-01

5.  Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets.

Authors:  P Needleman; A Raz; J A Ferrendelli; M Minkes
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

6.  Metabolism of arachidonic acid in ionophore-stimulated neutrophils. Esterification of a hydroxylated metabolite into phospholipids.

Authors:  W F Stenson; C W Parker
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

7.  Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes.

Authors:  J A Salmon; D R Smith; R J Flower; S Moncada; J R Vane
Journal:  Biochim Biophys Acta       Date:  1978-03-14

8.  Mechanism of arachidonic acid release in human polymorphonuclear leukocytes.

Authors:  C E Walsh; L R Dechatelet; F H Chilton; R L Wykle; M Waite
Journal:  Biochim Biophys Acta       Date:  1983-01-07

9.  Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets.

Authors:  M Hamberg; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1974-09       Impact factor: 11.205

10.  Plaque formation and isolation of pure lines with poliomyelitis viruses.

Authors:  R DULBECCO; M VOGT
Journal:  J Exp Med       Date:  1954-02       Impact factor: 14.307

View more
  2 in total

1.  Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative.

Authors:  J J Killackey; B A Killackey; R B Philp
Journal:  Agents Actions       Date:  1985-12

Review 2.  Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases.

Authors:  I Kadiu; J G Glanzer; J Kipnis; H E Gendelman; M P Thomas
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.